Merck dividend: cash coverage and yield
Merck's dividend rose from $2.64 to $3.28 per share in the history shown. Its cash covered dividends in 2025, but free cash flow also funded buybacks and acquisitions.
How much does Merck pay per share?
Dividends rise in the base from $3.55 to $3.75 and then $3.95 per share. That extends a record of annual increases from $2.64 to $3.28. The bear freezes the declared quarterly rate, producing $3.40 in each period. The bull reaches $3.60, $3.80 and $4.00 if cash generation permits faster increases, despite debt and research needs.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| EPS, diluted | 7.28 | 6.74 | 0.14 | 5.71 | 4.86 |
| Real free cash flow per share | 4.60 | 6.82 | 3.34 | 5.57 | 3.23 |
| − Dividends paid, per share | 3.26 | 3.09 | 2.92 | 2.76 | 2.60 |
| = FCF not paid out, per share | 3.52 | 0.13 | 3.02 |
Is Merck's dividend covered by its cash?
Free cash flow is the cash left after operations and spending on plants and equipment. From 2021 through 2025, it totalled $62,980 million. Dividends consumed $37,083 million and buybacks consumed another $8,576 million. Acquisitions absorbed $38,495 million, so operating cash alone could not fund both distributions and purchases.
The distribution test is demanding. Merck paid $8,176 million in dividends and spent $5,084 million repurchasing shares. Those uses exceeded conventional free cash flow before the Verona acquisition, which consumed $10,042 million net of acquired cash. The question is not whether one year’s adjusted EPS covers the dividend, but whether cash can fund distributions, factories and replacement research together.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Free cash flow | 12,360 | 18,096 | 9,143 | 14,707 | 8,674 |
| − Dividends paid | 8,176 | 7,840 | 7,445 | 7,012 | 6,610 |
| − Share buybacks | 5,084 | 1,306 | 1,346 | 0 | 840 |
| = Free cash flow not paid out | 8,938 | 327 | 7,682 | ||
| = Paid out more than the free cash flow | 912 |
What could change Merck's dividend?
Debt-funded acquisitions, lower free cash flow and reduced buybacks would also weaken the outlook. The bull case gains credibility if QLEX and newer launches expand beyond specialist use, vaccine inventory normalizes and several pipeline programs reach market before KEYTRUDA erosion accelerates.
| October 2027 | October 2028 | October 2029 | |
|---|---|---|---|
| Earnings | 21,600 (20,017 / 23,016) | 22,032 (19,028 / 24,480) | 20,071 (16,000 / 24,090) |
| Shares (millions) | 2,454 (2,460 / 2,448) | 2,447 (2,463 / 2,433) | 2,442 (2,470 / 2,420) |
| Dividends per share | 3.55 (3.40 / 3.60) | 3.75 (3.40 / 3.80) | 3.95 (3.40 / 4.00) |
| Price to earnings | 15.50 (13.00 / 17.00) | 15.00 (11.00 / 18.00) | 13.50 (9.00 / 17.00) |